See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: July 24, 2006

Migraine and Cluster Headaches High Cholesterol (Hyperlipidemia) Chronic Back Pain

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Migraine and Cluster Headaches

This clinical research study is seeking people with menstrual migraines. Female volunteers who are 18-65 years old may qualify. Participants will receive study-related medical care, investigational medicine, and compensation for time and travel.

The research site is in Oklahoma City, Okla.

More information

Please see


High Cholesterol (Hyperlipidemia)

People with high cholesterol with mixed dyslipidemia may qualify for this research study. Candidates who are at least 18 years of age, are willing to stop taking all lipid-regulating drugs other than the investigational study drug, and are willing to follow a diet recommended by the American Heart Association may be eligible. Participants will receive all study-related care and study medications at no cost.

The research site is in Colorado Springs, Colo.

More information

Please see


Chronic Back Pain

This research study will evaluate the safety and effectiveness of an extended release investigational drug in people with chronic low back pain. Candidates who are 21-75, have been diagnosed with chronic low back pain for at least six months, and are unable to control low back pain with current medication may be eligible. Participants will receive study-related medical care and study drug or placebo at no cost.

The research site is in Evansville, Ind.

More information

Please see


Copyright 2006 Thomson CenterWatch. All rights reserved.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.